[
  {
    "title": "Proposed $7.25B settlement to resolve weedkiller cancer lawsuits",
    "link": "https://www.statnews.com/2026/02/18/health-news-roundup-weedkiller-cancer-lawsuit/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-18T12:58:06.000Z",
    "summary": "And other health news from the Morning Rounds newsletter"
  },
  {
    "title": "STAT+: FDA reverses course, agrees to review Moderna’s flu vaccine",
    "link": "https://www.statnews.com/2026/02/18/fda-moderna-reverse-course-flu-vaccine/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-18T12:29:42.000Z",
    "summary": "The FDA reversed course and told Moderna it would review its application for a new flu vaccine, the company announced Wednesday."
  },
  {
    "title": "STAT+: Biotech startup raises $175 million to advance Alzheimer’s antibody therapy",
    "link": "https://www.statnews.com/2026/02/18/korsana-biosciences-alzheimers-brain-shuttles/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-18T11:00:00.000Z",
    "summary": "Is there room for more Alzheimer’s antibody therapies on the market? Korsana Biosciences' investors think so."
  },
  {
    "title": "Opinion: I was a Moderna exec when the Covid vaccine rolled out. That spirit of possibility is no more",
    "link": "https://www.statnews.com/2026/02/18/moderna-mrna-flu-vaccine-trust-regulatory-uncertainty/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-18T09:30:00.000Z",
    "summary": "“The pharmaceutical industry is not the enemy,” writes Richard Hughes IV, who was Moderna’s VP for public policy when the Covid vaccine rolled out."
  },
  {
    "title": "STAT+: As oncologists ponder how to integrate AI-powered cancer tools, products are hitting the market",
    "link": "https://www.statnews.com/2026/02/18/ai-powered-cancer-tools-new-digital-pathology-valar-labs/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-18T09:30:00.000Z",
    "summary": "Oncologists say there is promise in new AI tools that can guide them when choosing between two plausible treatments."
  },
  {
    "title": "Opinion: Same blood test, different results:  Why isn’t this common thyroid screening reliable?",
    "link": "https://www.statnews.com/2026/02/18/tsh-thyroid-stimulating-hormone-blood-test-pituitary-labs-standardized-assay/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-18T09:30:00.000Z",
    "summary": "Researchers have known for decades that different brands of lab machines produce different results. The fix is easy — but not enforced."
  },
  {
    "title": "PIP4K2C: an emerging fulcrum for multiple diseases",
    "link": "https://www.nature.com/articles/d41573-026-00030-8",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-18T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "STAT+: At drugmakers’ forum, Oz gets a friendly embrace, while Makary faces tough questions",
    "link": "https://www.statnews.com/2026/02/17/pharma-forum-highlights-industry-divide-oz-makary/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T23:28:45.000Z",
    "summary": "Two of health secretary Robert F. Kennedy Jr.’s top lieutenants struck decidedly different tones at a forum held Tuesday by the pharmaceutical industry group PhRMA."
  },
  {
    "title": "Bayer agrees to $7.25 billion proposed settlement over thousands of Roundup cancer lawsuits",
    "link": "https://www.statnews.com/2026/02/17/bayer-settlement-lawsuits-roundup-weedkiller-cancer/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T21:17:53.000Z",
    "summary": "Bayer has agreed to $7.25 billion proposed settlement over thousands of lawsuits alleging the company failed to warn people that its popular weedkiller Roundup could cause cancer."
  },
  {
    "title": "STAT+: A shakeup at HHS, a toast to bipartisanship, and a cheese poof war",
    "link": "https://www.statnews.com/2026/02/17/health-policy-news-who-is-leading-the-cdc/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T18:37:39.000Z",
    "summary": "You're reading the web edition of D.C. Diagnosis, STAT's guide to the ins and outs and oddities of health politics and policy"
  },
  {
    "title": "STAT+: The health care economy, and a surprising Humira chart",
    "link": "https://www.statnews.com/2026/02/17/health-care-inc-a-surprising-humira-chart-skyrizi/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T18:29:05.000Z",
    "summary": "This is the online version of the essential and fabulous Health Care Inc. newsletter"
  },
  {
    "title": "Compass, with Phase 3 hits, ready to take psilocybin to the FDA",
    "link": "https://www.biopharmadive.com/news/compass-trial-data-fda-application-psilocybin-psychedelics/812332/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-17T16:53:15.000Z",
    "summary": "The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.…"
  },
  {
    "title": "Ocular claims a win with eye drug data even as shares sink",
    "link": "https://www.biopharmadive.com/news/ocular-therapeutix-succeeded-phase-3-eye-drug-data-axpaxli-eylea/812329/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-17T16:07:37.000Z",
    "summary": "Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, analysts said."
  },
  {
    "title": "STAT+: Does Medicare’s ACCESS model pay enough?",
    "link": "https://www.statnews.com/2026/02/17/does-medicare-access-model-pay-enough-health-tech/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T15:31:50.000Z",
    "summary": "In this edition of STAT Health Tech: Payment rates for Medicare's ACCESS model, health insurers' use of AI, and more."
  },
  {
    "title": "STAT+: Psilocybin data could be good enough for approval",
    "link": "https://www.statnews.com/2026/02/17/biotech-news-compass-psilocybin-data-for-fda/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T14:57:05.000Z",
    "summary": "And other biotech news brought to you by The Readout newsletter"
  },
  {
    "title": "STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more",
    "link": "https://www.statnews.com/pharmalot/2026/02/17/india-ireland-china-glp-lilly-novo-obesity-vaccines-peanuts-africa/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T14:21:26.000Z",
    "summary": "The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews"
  },
  {
    "title": "Checking in on RFK Jr.’s promises, one year later",
    "link": "https://www.statnews.com/2026/02/17/health-news-rfk-jr-promises-one-year-later/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T14:05:59.000Z",
    "summary": "And other health news from the Morning Rounds newsletter"
  },
  {
    "title": "STAT+: Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial",
    "link": "https://www.statnews.com/2026/02/17/ocular-therapeutix-axpaxli-wet-amd-treatment-compared-to-eylea-regeneron/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T12:00:00.000Z",
    "summary": "Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question."
  },
  {
    "title": "STAT+: Compass says its psilocybin drug helped patients with severe depression in two trials",
    "link": "https://www.statnews.com/2026/02/17/compass-pathways-comp360-psilocybin-severe-depression-trial-results/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T11:30:00.000Z",
    "summary": "COMP360 could be the first psilocybin-based medicine to win approval."
  },
  {
    "title": "Selecting the optimal cell therapy manufacturing platform",
    "link": "https://www.biopharmadive.com/spons/selecting-the-optimal-cell-therapy-manufacturing-platform/812042/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-17T10:00:00.000Z",
    "summary": "Navigating modular vs. integrated platforms—find the best path for your cell therapy program."
  },
  {
    "title": "How to evaluate prospective diagnostic laboratory partners for your patient support program",
    "link": "https://www.biopharmadive.com/spons/how-to-evaluate-prospective-diagnostic-laboratory-partners-for-your-patient/810447/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-17T10:00:00.000Z",
    "summary": "As specialty medicines account for an increasing share of the drug pipeline, it makes sense for sponsors to support patients financially, emotionally and logistically."
  },
  {
    "title": "STAT+: As China’s drug industry races ahead, its GLP-1 race is accelerating too",
    "link": "https://www.statnews.com/2026/02/17/china-drug-industry-biotech-glp1/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T09:30:00.000Z",
    "summary": "To understand what China's fast-developing drug industry might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs."
  },
  {
    "title": "STAT+: In a financial pinch, major health insurers are turning to AI for help",
    "link": "https://www.statnews.com/2026/02/17/health-insurers-expand-ai-use-undermining-providers-trust/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T09:30:00.000Z",
    "summary": "Facing shrinking profits and higher costs, health insurers are accelerating adoption of AI throughout their sprawling operations."
  },
  {
    "title": "Opinion: AMA CEO: Deepfake doctors are a threat to public health",
    "link": "https://www.statnews.com/2026/02/17/deepfake-doctors-scam-ama/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T09:30:00.000Z",
    "summary": "Highly respected doctors on social media are endorsing questionable medical products — but they’re deepfakes, and they’re a serious problem."
  },
  {
    "title": "Opinion: When IV opioids are in short supply at the hospital, who gets pain relief?",
    "link": "https://www.statnews.com/2026/02/17/iv-opioid-shortages-ethics/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-17T09:30:00.000Z",
    "summary": "If IV opioids are in short supply, who gets pain relief — a teenager in agony with a crushed leg or an 80-year-old dying from cancer?"
  },
  {
    "title": "Therapeutic targeting of neuroimmune mechanisms in neurodegeneration",
    "link": "https://www.nature.com/articles/s41573-025-01370-7",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-16T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "TIGIT’s immuno-oncology teachings",
    "link": "https://www.nature.com/articles/d41573-026-00031-7",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-16T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "Vertex’s CRISPR therapy rebounds in latest earnings",
    "link": "https://www.biopharmadive.com/news/vertex-earnings-casgevy-q4-2025/812243/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T18:00:21.000Z",
    "summary": "Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report."
  },
  {
    "title": "Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs",
    "link": "https://www.biopharmadive.com/news/lyell-trial-biotech-europe-biogen-novocure-optum/812059/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T16:00:00.000Z",
    "summary": "Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for…"
  },
  {
    "title": "FDA removes box warnings for 6 menopausal therapies",
    "link": "https://www.biopharmadive.com/news/fda-removes-box-warning-six-menopausal-therapies-hrt/812146/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T15:16:12.000Z",
    "summary": "The FDA has lifted longstanding and the most severe warnings off of hormone replacement therapies for menopausal women."
  },
  {
    "title": "Ultragenyx cuts jobs as it seeks path to profit in 2027",
    "link": "https://www.biopharmadive.com/news/ultragenyx-cuts-jobs-profitability-earnings-2025-gene-therapy/812204/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T15:08:12.000Z",
    "summary": "Another FDA knockback for a gene therapy has investors and analysts redrawing expectations for the rare disease drug developer."
  },
  {
    "title": "Moderna shares jump as company affirms growth outlook",
    "link": "https://www.biopharmadive.com/news/moderna-fourth-quarter-2025-financial-earnings/812211/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T14:22:39.000Z",
    "summary": "The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback."
  },
  {
    "title": "HHS elevates officials into Kennedy’s inner circle in advance of midterms",
    "link": "https://www.biopharmadive.com/news/rfk-kennedy-elevates-counselors-hhs-midterms/812301/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T13:38:06.000Z",
    "summary": "The HHS secretary has four new senior advisors to help him “move faster and go further” on his Make America Healthy Again agenda."
  },
  {
    "title": "Approvals by the China NMPA in 2025",
    "link": "https://www.nature.com/articles/d41573-026-00028-2",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-13T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-12T16:17:42.000Z",
    "summary": "The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations…"
  },
  {
    "title": "FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-12T13:33:59.000Z",
    "summary": "The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer."
  }
]
